Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Partnered Content
Ask the Analyst
RSS Feeds
Subscribe
Advertise
Contact Us
FAQs
Reports Store
UsernamePublicRestriction
Tags:
Deals Biosimilars Middle East and Africa

Tabuk Makes MENA Deal For Prestige’s Trastuzumab

Pair Strike Agreement On Rights To Tuznue Biosimilar To Herceptin

  • News

Executive Summary

Saudi firm Tabuk has struck a deal to sell Prestige BioPharma’s Tuznue trastuzumab biosimilar in the MENA region.

You may also be interested in...



Deal Watch: ICON, PRA Health Form Massive CRO In $12bn Merger

Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia

Teva Takes Tuznue Trastuzumab Biosimilar In Israel From Prestige

Prestige BioPharma is continuing to put pen to paper on deals to supply and sell its HD201 biosimilar trastuzumab candidate, this time partnering with Israeli giant Teva for local commercialization rights.

Pharmapark Will Market Prestige's Trastuzumab In Russia

Prestige BioPharma has struck a deal with Pharmapark to market Prestige’s trastuzumab biosimilar in the Russian Federation.

Table

View full table

Related Content

Generics Bulletin

Topics

Related Companies

Tags:
Deals Biosimilars Middle East and Africa
UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By